Cool-associated Tyrosine-phosphorylated Protein 1 Is Required for the Anchorage-independent Growth of Cervical Carcinoma Cells by Binding Paxillin and Promoting AKT Activation.

Sungsoo M. Yoo  
*Thomas Jefferson University; Cornell University, sungsoo.yoo@jefferson.edu*

Arash Latifkar  
*Cornell University*

Richard A. Cerione  
*Cornell University*

Marc A. Antonyak  
*Cornell University*

Let us know how access to this document benefits you  
Follow this and additional works at: [http://jdc.jefferson.edu/bmpfp](http://jdc.jefferson.edu/bmpfp)  
Part of the [Medical Biochemistry Commons](http://jdc.jefferson.edu/bmpfp)

**Recommended Citation**  
[http://jdc.jefferson.edu/bmpfp/116](http://jdc.jefferson.edu/bmpfp/116)
Cool-associated Tyrosine-phosphorylated Protein 1 Is Required for the Anchorage-independent Growth of Cervical Carcinoma Cells by Binding Paxillin and Promoting AKT Activation*

Received for publication, November 22, 2016, and in revised form, January 18, 2017. Published, JBC Papers in Press, January 18, 2017, DOI 10.1074/jbc.M116.769190

Sungsoo M. Yoo 1, Arash Latifkar 1,5, Richard A. Cerione 2,4,†, and Marc A. Antonyak 1

From the Departments of 6Molecular Medicine, College of Veterinary Medicine and 6Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, New York 14853 and the 5Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Edited by Jeffrey E. Pessin

Cool-associated tyrosine-phosphorylated protein 1 (Cat-1) is a signaling scaffold as well as an ADP-riboseylation factor-GTPase-activating protein. Although best known for its role in cell migration, we recently showed that the ability of Cat-1 to bind paxillin, a major constituent of focal complexes, is also essential for the anchorage-independent growth of HeLa cervical carcinoma cells. Here we set out to learn more about the underlying mechanism by which Cat-paxillin interactions mediate this effect. We show that knocking down paxillin expression in HeLa cells promotes their ability to form colonies in soft agar, whereas ectopically expressing paxillin in these cells inhibits this transformed growth phenotype. Although knocking down Cat-1 prevents HeLa cells from forming colonies in soft agar, when paxillin is knocked down together with Cat-1, the cells are again able to undergo anchorage-independent growth. These results suggest that the requirement of Cat-1 for this hallmark of cellular transformation is coupled to its ability to bind paxillin and abrogate its actions as a negative regulator of anchorage-independent growth. We further show that knocking down Cat-1 expression in HeLa cells leads to a reduction in Akt activation, which can be reversed by knocking down paxillin. Moreover, expression of constitutively active forms of Akt1 and Akt2 restores the anchorage-independent growth capability of HeLa cells depleted of Cat-1 expression. Together, these findings highlight a novel mechanism whereby interactions between Cat-1 and its binding partner paxillin are necessary to ensure sufficient Akt activation so that cancer cells are able to grow under anchorage-independent conditions.

Cool-associated tyrosine-phosphorylated protein 1 (Cat-1),2 also referred to as G protein-coupled receptor kinase interactor 1 (GIT-1), is thought to serve as a signaling scaffold/adaptor protein that binds a number of different protein partners to mediate actin cytoskeletal changes and cell migration (1–3). It also functions as a GAP for Arf1 and Arf6, two members of the Arf family of small GTPases that have been implicated in the regulation of trafficking events in cells (4–6). Recently, we found that Cat-1 is overexpressed in a large number of human cervical carcinomas and that knocking down its expression in HeLa cells using siRNAs blocked the ability of these cells to exhibit anchorage-independent growth (6) (i.e. as assayed by colony formation in soft agar), a hallmark of cancer and transformed cells (7). We then went on to show that introducing an siRNA-insensitive form of wild-type Cat-1 into HeLa cells, where endogenous Cat-1 expression was knocked down, restored their ability to form colonies in soft agar. On the other hand, introducing an siRNA-insensitive mutant form of Cat-1, defective in binding paxillin, was unable to restore this transformed phenotype. These findings indicated that the interaction between Cat-1 and paxillin was critical for the Cat-1-mediated anchorage-independent growth of HeLa cells.

Paxillin is another signaling scaffold/adapter protein that has been shown to play important roles in regulating focal adhesion dynamics and integrin-mediated signaling events (8). As one of the first proteins to be identified as a constituent of focal complexes (9), paxillin was shown to accumulate at nascent focal complexes in migrating cells (10). It was also demonstrated through mutagenesis studies that disrupting the phosphorylation of paxillin by tyrosine kinases such as the focal adhesion kinase or blocking the ability of paxillin to interact with proteins like Cat or tubulin, alters focal complex dynamics, resulting in irregular cell spreading and defects in cell migration (11, 12).

In addition to being important for the adhesion and migration of a wide variety of cell types, various reports have also implicated paxillin in the growth and survival of certain forms of human cancer. Indeed, the transcript and protein levels of paxillin are frequently up-regulated in several types of cancer, including oral, bone, and colorectal tumors (13–17). In colorectal tumors, survival analyses performed on patients revealed a correlation between the extent of paxillin expression and clinical outcome; the prognosis of patients showing a relatively high expression of paxillin was poorer compared with those with low
Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

paxillin expression (16). In such cases, the potential roles of paxillin in cell migration and invasiveness are likely to come into play in the development of these aggressive cancers. It has also been reported that paxillin can contribute to the promotion of anchorage-independent growth of certain colon cancer cell lines, DLD1 and HCT116, as well as fibroblasts stably expressing the constitutively active H-Ras G12V mutant (16, 18). However, there has also been a report where paxillin expression was negatively correlated with metastasis (19), and, as described below, how paxillin contributes to the ability of cancer cells to exhibit anchorage-independent growth appears to be context-dependent.

In this study, we set out to understand the underlying mechanism by which the paxillin binding partner, Cat-1, promoted the anchorage-independent growth of human cervical carcinoma cells (6). Given our previous findings highlighting an essential role played by Cat-1 in HeLa cell transformation (6), together with the suggestions that paxillin contributes to cancer progression (13–18), we initially suspected that the two proteins might work together in a signaling complex to send a stimulatory signal that would promote anchorage-independent growth. However, we found that paxillin exerts a negative regulatory effect on this transformed growth phenotype, whereas Cat-1, by binding to paxillin, is able to repress its negative regulatory activity and thereby promote anchorage-independent growth. Thus, the inhibition of anchorage-independent growth caused by knocking down Cat-1 expression in HeLa cells can be overcome by knockdown of paxillin expression. Moreover, these effects on anchorage-independent growth and transformation appear to be driven by changes in Akt activity. Specifically, knockdown of Cat-1 resulted in lower levels of Akt activation, whereas knocking down paxillin enhanced Akt activity. We then found that expressing activated forms of Akt1 and Akt2 was able to restore anchorage-independent growth in cells where Cat-1 expression had been knocked down. Collectively, these results point to new and unexpected roles for Cat-1 and paxillin in the regulation of anchorage-independent growth in human cervical carcinoma cells, whereby Cat-1 promotes this transformed phenotype by mitigating the negative regulatory actions of paxillin.

Results

Knocking Down Paxillin Expression Enhances Anchorage-independent Growth—The Cat-1-mediated anchorage-independent growth of HeLa cervical carcinoma cells is dependent on its ability to bind paxillin, a major scaffold/adaptor protein found in focal complexes (6). Here we wanted to build upon these findings by determining the mechanism by which Cat-1-paxillin interactions promote this transformed phenotype. To begin, HeLa cells that had been either mock-transfected or transfected with a construct encoding a GFP-tagged form of wild-type paxillin (GFP-Pxn WT) to label focal complexes were stained with GFP and Cat-1 antibodies. Fig. 1A shows that little GFP signal was detected in mock-transfected cells (Mock Transfected, GFP), whereas Cat-1 was expressed in structures that resembled focal complexes (Mock Transfected, Cat-1). When paxillin was ectopically expressed in the cells, it localized with Cat-1 (Fig. 1A, Transfected with GFP-Pxn WT, GFP and Cat-1), confirming that both of these proteins do indeed reside in focal complexes.

We introduced a control siRNA or two different siRNAs targeting paxillin into HeLa cells and then assayed the ability of these cells to form colonies in soft agar (i.e. anchorage-independent growth). Fig. 1B, top panel, shows that both paxillin siRNAs (Pxn siRNA 1 and Pxn siRNA 2) knocked down endogenous paxillin expression compared with the control siRNA (Cont. siRNA). Pxn siRNA 1 reduced paxillin levels by ~70%, whereas Pxn siRNA 2 consistently reduced paxillin expression by ~95%. Given the findings from several studies linking paxillin to cell growth and survival, we initially suspected that knocking down paxillin in HeLa cells would compromise their ability to grow in soft agar. However, Fig. 1C shows that this was not the case. In fact, knocking down paxillin expression led to the formation of more colonies in soft agar compared with cancer cells expressing control siRNA (Fig. 1C, compare the Cont.
siRNA column with the Pxn siRNA 1 and 2 columns), with the largest increase in colony formation being achieved when using the paxillin siRNA that most effectively reduced paxillin expression (i.e. Pxn siRNA 2, Fig. 1C).

An analogous set of experiments was carried out using NIH3T3 mouse fibroblasts that were transformed by the stable expression of a constitutively active Cdc42 mutant (Cdc42(F28L)), as we had found previously that these cells exhibited anchorage-independent growth in a manner dependent on Cat-1, similar to human cervical carcinoma cell lines (6). Control siRNA or Pxn siRNA 1 was introduced into fibroblasts expressing the activated Cdc42(F28L) mutant (Fig. 1D, top panel), prior to the cells being placed in soft agar. Fig. 1E shows that knocking down paxillin expression by 30%-50% resulted in a corresponding increase in the amount of colonies formed by NIH3T3 cells expressing Cdc42(F28L).

Because decreasing paxillin levels in HeLa cancer cells using siRNAs promoted their ability to grow under anchorage-independent conditions, we then examined whether overexpressing paxillin in these cells yielded the opposite effect. Compared with cells expressing vector alone, the amount of colonies generated by HeLa cells ectopically expressing GFP-tagged wild-type paxillin (Fig. 2A, top panel, Pxn WT) was reduced by ~45% (Fig. 2B, compare the Vector and Pxn WT columns), which was similar to the reduction in colonies observed when HeLa cells were transfected with a V5-tagged dominant-negative form of Cat-1 that is unable to function as an Arf GAP or bind paxillin (6), referred to as Cat-1 KK-RA (Fig. 2, A, center panel, Cat-1 KK-RA, and B, compare the Cat-1 KK-RA and Pxn WT columns).

The Binding of Cat-1 to Paxillin Reverses Its Negative Regulatory Effects on Anchorage-independent Growth—The findings described in the preceding section suggest that paxillin might function in certain types of cells (i.e. cervical carcinoma cells and transformed fibroblasts) as a negative regulator of anchorage-independent growth. When considered together with our previous findings that Cat-1 needs to interact with paxillin to promote the growth of HeLa cells in soft agar (6), these results raised the intriguing possibility that Cat-1, by binding to paxillin, represses a negative regulatory effect exerted by paxillin on anchorage-independent cell growth. This further suggested that the inability of HeLa cells to exhibit a transformed growth phenotype under conditions where Cat-1 has been knocked down should be reversed by the simultaneous knockdown of paxillin. To directly investigate this possibility, we knocked down the expression of Cat-1 alone versus knocking down both Cat-1 and paxillin expression (Fig. 3A, compare the Cont. siRNA lane with the Cat-1 siRNA and Cat-1 siRNA and Pxn siRNA lanes) and then performed anchorage-independent growth assays on the cells. As shown previously (6), knocking...
down Cat-1 expression in HeLa cells markedly reduced their ability to form colonies in soft agar (Fig. 3B, compare the Cont. siRNA and Cat-1 siRNA columns). However, under conditions where both Cat-1 and paxillin expression was knocked down, HeLa cells again formed colonies nearly as well as cells expressing the control siRNA (Fig. 3B, Cat-1 siRNA and Pxn siRNA). These findings are consistent with the idea that Cat-1 binds paxillin and represses its ability to inhibit anchorage-independent growth.

**Cat-1 Maintains Akt Activation**—We next set out to better understand how the formation of Cat-1-paxillin complexes positively supported anchorage-independent cell growth. Various intracellular signaling events have been implicated in the growth and survival responses required for cells to grow under anchorage-independent conditions, with one of the more common examples being the activation of the mTOR complex 1 and 2 (mTORC1 and mTORC2)-Akt pathway (20). To determine whether the binding of Cat-1 to paxillin could alter the activation of this pathway, HeLa cells were grown in suspension, and the resulting spheres that formed were stained with various combinations of antibodies that recognize paxillin, Cat-1, and Akt when it is phosphorylated at Ser-473. As a negative control, spheres were also stained with only the fluorescently conjugated secondary antibodies (Green or Red Secondary Ab), whereas paxillin appeared as small puncta throughout the cytosol of many of the HeLa cells that comprised the spheres (Pxn). Importantly, both Cat-1 (Fig. 4, Cat-1) and phosphorylated Akt (Fig. 4, P-Akt (Ser473)) localized with paxillin, suggesting that there might be a functional connection between these proteins.

We next introduced control siRNA or a Cat-1-targeted siRNA into HeLa cells and then analyzed the lysates generated from these cells by Western blotting analysis using antibodies that detect the phosphorylated (activated) forms of Akt and ERK, another protein that is important for mediating the anchorage-independent growth of some cancer cell types (20). Although we were unable to consistently detect changes in ERK activation following knockdown of Cat-1 in these cells (Fig. 5A, third panel, compare the Cont. siRNA and Cat-1 siRNA lanes), the phosphorylation levels of Akt at Ser-473 were significantly reduced (Fig. 5A, first panel, compare the Cont. siRNA and Cat-1 siRNA lanes). Akt phosphorylation was then restored by knocking down paxillin expression in cells that were already depleted of Cat-1 (Fig. 5A, first panel, compare the Cat-1 siRNA and Cat-1 and Pxn siRNA lanes). Interestingly, HeLa cells in which only paxillin was knocked down showed a much greater degree of phosphorylated Akt than their counterparts expressing control siRNA (Fig. 5B, top panel). These findings, combined with the fact that Akt phosphorylation is reduced in HeLa cells ectopically expressing wild-type paxillin (Fig. 5C, top panel), suggests that paxillin in some way imparts a negative regulation of Akt activation that can be abrogated upon binding of Cat-1 to paxillin.

Because the phosphorylation state of paxillin has been shown to influence its ability to regulate some cellular processes (i.e. promote focal complex turnover) (8–12), we determined whether paxillin phosphorylation might be important for inhibiting Akt activity. Lysates of HeLa cells expressing control siRNA or a Cat-1 siRNA were immunoblotted with an antibody that detects paxillin when it is phosphorylated at Tyr-118, a major regulatory site (8, 11, 12). However, only a slight increase in the levels of phosphorylated paxillin could be detected in cells in which Cat-1 expression was knocked down (Fig. 5D, top panel). The same experiment was also carried out on HeLa cells maintained in suspension, a condition that more closely reflects cells grown under anchorage-independent (soft agar) conditions. As expected, the levels of paxillin phosphorylation at Tyr-118 dramatically decreased in suspended cells expressing control siRNA compared with the same cells grown attached to a culture plate (Fig. 5E, first panel, compare the Attached cells expressing Cont. siRNA lane with the Suspended cells expressing Cont. siRNA lane). The phosphorylation of paxillin in suspended HeLa cells depleted of Cat-1 expression did not change (Fig. 5E, first panel, compare the Suspended cells...
expressing Cont. siRNA lane with the Suspended cells expressing Cat-1 siRNA lane) even though Akt phosphorylation decreased under these same conditions (Fig. 5E, third panel). Thus, changes in the phosphorylation state of paxillin do not appear to be directly responsible for its ability to negatively regulate the activation of Akt in HeLa cells.

We then determined whether the effect of knocking down Cat-1 expression on the phosphorylation of Akt was specific for a particular Akt isoform. The Akt family of proteins is made up of three highly related members, Akt1, Akt2, and Akt3. Akt1 and Akt2 are ubiquitously expressed and have been linked to the activation of Akt in HeLa cells.

The Akt family of proteins is made up of three highly related members, Akt1, Akt2, and Akt3. Akt1 and Akt2 are ubiquitously expressed and have been linked to the activation of Akt in HeLa cells. Akt1, Akt2, and Akt3. Akt1 and Akt2 are ubiquitously expressed and have been linked to the activation of Akt in HeLa cells.

We then determined whether the effect of knocking down Cat-1 expression on the phosphorylation of Akt was specific for a particular Akt isoform. The Akt family of proteins is made up of three highly related members, Akt1, Akt2, and Akt3. Akt1 and Akt2 are ubiquitously expressed and have been linked to the promoting cell growth and survival responses, whereas Akt3 is expressed primarily in the brain (21), making it unlikely that this isoform would be playing a role in cervical carcinoma cells. Thus, we focused on Akt1 and Akt2. The lysates collected from HeLa cells expressing either control siRNA or Cat-1-targeted siRNA (Fig. 6A) were immunoblotted with Akt1- and Akt2-specific antibodies. Under conditions where Cat-1 expression was markedly reduced (Fig. 6A, top panel, Cat-1 siRNA), the overall levels of Akt1 and Akt2 were unchanged (Fig. 6A, center and bottom panels, compare the Cont. siRNA and Cat-1 siRNA lanes). To determine the extent to which each Akt isoform was activated, the same cell lysates were then probed with antibodies that can distinguish between Akt1 and Akt2 when they are phosphorylated at Ser-473. Fig. 6B shows that, under conditions where Cat-1 expression was knocked down in HeLa cells, the phosphorylation levels of Akt1 (left panel) and Akt2 (right panel) were decreased, suggesting that Cat-1 regulates the activity of both of these Akt isoforms.

**Akt Activation Is Necessary for Anchorage-independent Growth**—We next examined whether Akt activity was important for the Cat-1-mediated anchorage-independent growth of HeLa cancer cells by knocking down either Akt1 or Akt2, individually or in combination (Fig. 7A), and assaying their ability to form colonies in soft agar. HeLa cells expressing control siRNA (as a positive control) or Cat-1 siRNA (as a negative control) were also assayed. Knocking down the expression of either Akt isoform reduced the amount of colonies formed in soft agar, although knockdown of Akt2 consistently had a greater effect (Fig. 7B, compare the Cont. siRNA column with the Akt1 siRNA and Akt2 siRNA columns). Interestingly, simultaneous knockdown of both Akt1 and Akt2 or treatment of HeLa cells with an Akt inhibitor (Akt inhibitor VIII), a cell-permeable inhibitor that blocks both Akt isoforms, decreased colony formation by HeLa cells to a similar extent as knocking down Cat-1 (Fig. 7B, compare the Cont. siRNA column with the Akt1 plus Akt2 columns).
siRNA and Akt inhibitor VIII columns). These results suggest that the role of Cat-1 in helping maintain the activation of Akt is necessary for the anchorage-independent growth of HeLa cells.

We then went on to determine whether maintaining Akt activity in HeLa cells, under conditions where Cat-1 was knocked down, restored their ability to exhibit anchorage-independent growth. Specifically, we tested constitutively active forms of Akt1 and Akt2 in which aspartic acid residues replaced Thr-308 and Ser-473, i.e. the key residues that need to be phosphorylated for activation (20–23). The cells were then transfected with siRNAs targeting Cat-1 and assayed for colony formation in soft agar to see whether the constitutively active Akt mutants could reverse the inhibition of colony formation caused by knocking down Cat-1 expression. Fig. 8. A and B, shows that the expression of a phosphomimetic Akt1 or Akt2 mutant in cells where endogenous Cat expression had been knocked down, gave rise to a partial recovery of the ability of HeLa cells to grow in soft agar. However, co-expression of the phosphomimetic Akt1 and Akt2 mutants in HeLa cells in which Cat-1 expression was knocked down led to a complete rescue of anchorage-independent growth (Fig. 8B, compare the Cat-1 siRNA column with the Cat-1 siRNA plus Akt1 DD and Akt2 DD columns).

Cat-1 Mediates an Inverse Relationship between Akt and p70S6 Kinase Activation—These results indicate that Akt activation plays a key role in the ability of Cat-1 to promote anchorage-independent growth, although the molecular mechanism linking Cat-1 to Akt was unknown. However, we found that, in HeLa cells, there was an inverse relationship between the activation of Akt and p70S6 kinase so that when Akt activation was reduced as a result of knocking down Cat-1 expression, there was a concomitant increase in p70S6 kinase activation (Fig. 9A, first and third panels, Cat-1 siRNA). The opposite was true when paxillin expression was knocked down; Akt activity was increased, whereas the activating phosphorylation of p70S6 kinase was decreased (Fig. 9A, first and second panels, Pxn siRNA). These results are consistent with findings that show that excessive mTORC1-p70S6 kinase activity leads to the down-regulation of PI3 kinase and, in turn, mTORC2 and Akt (22, 23).

We hypothesized that the down-regulation of Akt activity in HeLa cells where Cat-1 expression had been knocked down was caused by the up-regulation of p70S6 kinase activity. This led us to examine whether treating cells in which Cat-1 expression had been knocked down with rapamycin to reduce mTORC1 and p70S6 kinase activation would restore Akt activity. Indeed, rapamycin treatment restored Akt activation in cells where Cat-1 expression was knocked down (Fig. 9B, first panel, compare the Cat-1 siRNA lane with the Cat-1 siRNA plus Rapa-
Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

Discussion

Cat-1 is a GAP that can inactive members of the Arf GTase family (i.e. Arf1 and Arf6). It also serves as a protein scaffold that has the potential to interact with a variety of binding partners, including Cool-1/Pix-1 and paxillin (1–3). Although Cat-1 is best known for its roles in regulating cell morphology and promoting cell migration (2, 29, 30), there has been accumulating evidence suggesting that Cat-1 can also contribute to several different aspects of cancer progression. For example, Cat-1 has been shown to be important for highly
aggressive forms of breast (31), lung (32), and oral cancers (33) to metastasize to secondary sites as well as for the growth of liver and colon cancer cells (34). Moreover, we have recently shown that Cat-1 is overexpressed in a large majority of cervical carcinomas and is essential for the HeLa cervical cancer cell line to grow under anchorage-independent conditions. However, the mechanisms through which Cat-1 mediates its effects, especially as they pertain to the growth of cancer and transformed cells, are still not well understood.

Here we show that Cat-1 promotes the anchorage-independent growth of HeLa cells as well as fibroblasts that are transformed through the ectopic expression of an activated Cdc42 mutant as an outcome of its ability to interact with paxillin. Given the several connections linking paxillin to cancer progression (13–18), we initially assumed that Cat-1 and paxillin worked together to send a stimulatory signal that promoted this transformed phenotype. Instead, however, we discovered that Cat-1 interacts with paxillin to negatively regulate mTORC1/p70S6 kinase activation to an extent that ensures maximal activation of the cell growth/survival protein Akt (35). A working model that is consistent with the results we have obtained thus far is presented in Fig. 11. In this model, the role of Cat-1 is to antagonize the positive regulation of Arf1 by paxillin and thereby prevent it from signaling the activation of mTORC1 and p70S6 kinase, which, in turn, removes a negative regulation of mTORC2 and Akt normally mediated by activated p70S6 kinase. Thus, the positive actions of Cat-1 on Akt activation and, ultimately, anchorage-independent growth are an outcome of Cat-1 binding to paxillin and exerting its Arf-GAP activity, which would reverse any activation of Arf1 induced by paxillin alone. Knocking down Cat-1 has a negative effect on anchorage-independent growth through the loss of its antagonistic properties on the Arf1-mTORC1-p70S6 kinase pathway. However, knocking down paxillin removes a positive stimulatory input into this pathway (i.e. by eliminating the paxillin-mediated activation of Arf1) and thereby eliminates the deleterious effects caused by knocking down Cat-1. It is interesting to note that this newly described role for Cat-1 is similar to that of ...
The Arf1-mTORC1-p70S6 kinase pathway is activated, leading to right down (FIGURE 11. Cat-1 functions in HeLa cells to promote cellular transformation. Cat-1 binds to paxillin to abrogate its actions as a negative regulator of anchorage-independent growth (left). Specifically, the interaction between Cat-1 and paxillin perturbs the ability of paxillin to activate the Arf1-mTORC1-p70S6 kinase pathway, which ensures that the necessary level of Akt activation needed for supporting anchorage-independent growth (i.e. colony formation in soft agar) is met. However, under conditions where Cat-1 is knocked down (right), the Arf1-mTORC1-p70S6 kinase pathway is activated, leading to a p70S6 kinase-mediated negative regulation of Akt activity and loss of anchorage-independent growth.

Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation

DEP domain-containing mTOR-interacting protein (DEPTOR), a protein that was identified as an inhibitor of mTORC1 activation (36). When overexpressed in multiple myeloma cells, DEPTOR promotes cell survival by suppressing mTORC1 activity and promoting Akt activity.

It seems likely that the positive and negative inputs provided by paxillin and Cat-1 into the Arf1-mTORC1-p70S6 kinase pathway need to be very carefully balanced. Moreover, it is easy to imagine how, in some types of cancers, the stimulatory input provided by paxillin into the mTORC1/p70S6 kinase pathway may have a positive role in cancer cell growth and survival, as has sometimes been reported. Our future efforts will be directed toward understanding how the Cat-1-mediating signaling balance outlined in Fig. 11 is achieved in different contexts of malignant transformation as well as identifying additional proteins that play a role in this pathway. It will also be important to learn more about how Akt contributes stimulatory signals to the ability of cancer cells to exhibit anchorage-independent growth.

Experimental Procedures

Reagents—The Cat-1/Git-1 (catalog no. sc-13961), Arf1 (catalog no. sc-53168), and GFP (catalog no. sc-8334) antibodies were purchased from Santa Cruz Biotechnology and used at 1:500 dilutions. The phospho-p70S6 kinase (catalog no. 9205), p70S6 kinase (catalog no. 9202), phospho-Akt (Ser-473, catalog no. 4060), pan-Akt (catalog no. 9272), Akt1 (catalog no. 2938), Akt2 (catalog no. 2964), phospho-Akt1 (Ser-473, catalog no. 9018), phospho-Akt2 (Ser-474, catalog no. 8599), phospho-ERK (catalog no. 4370), ERK (catalog no. 9102), V5 (catalog no. 13202), HA (catalog no. 3724), actin (catalog no. 8456), and phospho-paxillin (Tyr-118, catalog no. 2541) primary antibodies as well as the mouse and rabbit IgG horseradish peroxidase-conjugated secondary antibodies (catalog nos. 7074 and 7076, respectively), were from Cell Signaling Technology and used at 1:2000 dilutions. The paxillin antibody (catalog no. 05-417) was from EMD Millipore and used at a 1:1000 dilution. AKT inhibitor VIII (catalog no. 124018) and rapamycin (catalog no. 553210) were also from EMD Millipore and used at 0.2 μM and 0.1 μM, respectively. INK 128 (catalog no. S2811) was from Selleckchem and used at 0.5 μM. The precast 4–20% Tris/glycine acrylamide gels were from Thermo Fisher Scientific. The PVDF transfer membrane and the Western Lighting Plus ECL reagent were from PerkinElmer Life Sciences. The protein G-agarose beads and all cell culture reagents, including RPMI 1640 medium, DMEM, calf serum, FBS, Lipofectamine, and puromycin, as well as the control siRNA and siRNAs targeting Cat-1, paxillin, Akt1, Akt2, and Arf1, were purchased from Invitrogen.

Plasmids—The V5-tagged pcdNA3 expression construct encoding a dominant negative form of rat Cat-1 (Cat-1 KK-RA), the pEGF expression construct encoding chicken paxillin, and the HA-tagged lentiviral vector pCDH-CMV-MOS-EF1-Puro (System BioSciences) encoding human Akt1 and Akt2 were generated previously (6). The constitutively active mutant forms of Akt1, termed Akt1 DD (T308D/S473D), and Akt2, termed Akt2 DD (T309D/S474D), were generated using the QuickChange™ site-directed mutagenesis kit (Stratagene).

Lentivirus Generation—The HA-tagged lentiviral vector pCDH-CMV-MOS-EF1-Puro encoding wild-type and mutant forms of Akt1 and Akt2 were transfected into HEK293T cells using Lipofectamine (Invitrogen). The mature lentiviruses shed into the culturing medium from the transfectants were collected and processed according to the instructions of the manufacturer (System BioSciences).

Cell Culture—HeLa cells were grown in RPMI 1640 medium containing 10% FBS, whereas NIH3T3 cells stably expressing an activated form of Cdc42 (Cdc42 F28L) were grown in DMEM containing 10% calf serum. The siRNAs and the expression constructs encoding various forms of Cat-1 and paxillin were transfected into cells using Lipofectamine (Invitrogen). The mature lentiviruses shed into the culturing medium from the transfectants were collected and processed according to the instructions of the manufacturer (System BioSciences).

Immunofluorescence—HeLa cells grown on glass coverslips were either mock-transfected, or transfected with a construct encoding GFP-tagged wild-type paxillin. In certain cases, HeLa cells were also grown under anchorage-independent conditions by plating them on bacteria-grade dishes and allowing them to form spheres. The cells grown on coverslips or in suspension as spheres were fixed with 3.7% formaldehyde, permeabilized with PBS containing 0.1% Triton X-100, and then blocked with 10% bovine serum albumin diluted in PBS. The cells were incubated with GFP, phospho-Akt (Ser-473), and Cat-1 antibodies at 1:500 dilutions, whereas the paxillin clone 165 antibody (catalog no. 610620) from BD Biosciences was used at a 1:200 dilution. The primary antibodies were detected using Alexa Fluor 488-conjugated anti-mouse (catalog no. A-11034) and Rhodamine-conjugated anti-rabbit (catalog no. R-6394) secondary antibodies from Molecular Probes at 1:800 dilutions. DAPI was used to label nuclei. Digital images of the cells were captured using a Zeiss fluorescence microscope outfitted with a Sensicam qe camera (Cooke Co.) and processed using IPLABS software (BD Biosciences).
**Cat-1/Git-1 Binds Paxillin and Promotes AKT Activation**

**Immunoblot Analysis**—Cells were lysed with cell lysis buffer (25 mM Tris (pH 7.4), 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM DTT, 1 mM NaVO₄, 1 mM β-glycerol phosphate, 1 mM aprotinin, 1 mM leupeptin, and 1 mM PMSF). The lysates were resolved by SDS-PAGE, and then the proteins were transferred to PVDF membranes. The membranes were incubated with the indicated primary antibodies diluted in 20 mM Tris (pH 7.4), 135 mM NaCl, and 0.02% Tween 20. The primary antibodies were detected with horseradish peroxidase-conjugated secondary antibodies followed by exposure to ECL reagent.

**Immunoprecipitations**—Cell extracts (typically 500 µg of each) were incubated with primary antibodies for 2 h at 4 °C with rotation. Protein G-agarose beads were then added to the lysates for an additional hour, at which point the beads were washed extensively with cell lysis buffer before being resuspended in Laemmli sample buffer and boiled.

**Soft-agar Assays**—HeLa cells and NIH3T3 cells stably expressing Cdc42 F28L, transfected with various siRNAs or penced in Laemmli sample buffer and boiled.

**References**


Cool-associated Tyrosine-phosphorylated Protein 1 Is Required for the Anchorage-independent Growth of Cervical Carcinoma Cells by Binding Paxillin and Promoting AKT Activation

Sungsoo M. Yoo, Arash Latifkar, Richard A. Cerione and Marc A. Antonyak

doi: 10.1074/jbc.M116.769190 originally published online January 18, 2017

Access the most updated version of this article at doi: 10.1074/jbc.M116.769190

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 36 references, 18 of which can be accessed free at
http://www.jbc.org/content/292/9/3947.full.html#ref-list-1